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Abstract
 
Interleukin (IL)-5 and IL-13 are thought to play key roles in the pathogenesis of asthma. Al-
though both cytokines use eotaxin to regulate eosinophilia, IL-13 is thought to operate a sepa-
rate pathway to IL-5 to induce airways hyperreactivity (AHR) in the allergic lung. However,
identification of the key pathway(s) used by IL-5 and IL-13 in the disease process is con-
founded by the failure of anti–IL-5 or anti–IL-13 treatments to completely inhibit the accumu-
lation of eosinophils in lung tissue. By using mice deficient in both IL-5 and eotaxin (IL-5/
eotaxin
 
 
 
/
 
 
 
) we have abolished tissue eosinophilia and the induction of AHR in the allergic
lung. Notably, in mice deficient in IL-5/eotaxin the ability of CD4
 
  
 
T helper cell (Th)2 lym-
phocytes to produce IL-13, a critical regulator of airways smooth muscle constriction and ob-
struction, was significantly impaired. Moreover, the transfer of eosinophils to IL-5/eotaxin
 
 
 
/
 
 
 
mice overcame the intrinsic defect in T cell IL-13 production. Thus, factors produced by eo-
sinophils may either directly or indirectly modulate the production of IL-13 during Th2 cell
development. Our data show that IL-5 and eotaxin intrinsically modulate IL-13 production
from Th2 cells and that these signaling systems are not necessarily independent effector path-
ways and may also be integrated to regulate aspects of allergic disease.
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Introduction
 
Allergic asthma is recognized as a chronic inflammatory
disease of the airways that is characterized by reversible air-
ways obstruction in association with aberrant CD4
 
  
 
Th 2
lymphocyte responses to common environmental stimuli
(1, 2). The hallmark features of allergic asthma, elevated
serum IgE, mucus hypersecretion, eosinophilia, and en-
hanced bronchial reactivity, or airways hyperreactivity
(AHR),
 
* 
 
to nonspecific spasmogenic stimuli, have all been
linked to the effector functions of Th2 cytokines (e.g., IL-4,
IL-5, IL-9, IL-10, and IL-13) and Th2 cells are obligatory
for the development and expression of disease (2). Impor-
tantly, it is these pathogenic processes that are thought to
promote airways obstruction in asthma, which predisposes
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to wheezing, shortness of breath, and life-threatening limi-
tations in airflow.
Although the etiology and pathophysiology of asthma
are complex, two independent models have been proposed
as possible key mechanisms whereby Th2 cells regulate dis-
ease processes that predispose to structural and functional
alterations of the airways. The first model identifies IL-5–
regulated eosinophilia as a central pathogenic pathway. IL-5
regulates eosinophil function (development, activation,
migration, and survival) and is a critical molecular switch
for the induction of blood and tissue eosinophilia. This
model is based on extensive clinical and experimental in-
vestigations that show a strong correlation between IL-5,
eosinophils, and their secreted products with the severity
and exacerbation of disease (3–12). The second model pro-
vides evidence that IL-13 underscores the development of
mucus hypersecretion and AHR in the allergic lung, and
implies dissociation between eosinophilia and these phe-
nomena (13, 14). Although in comparison to IL-5 the data
on the role of IL-13 in asthma are limited, the potency of
this molecule in inducing AHR and mucus hypersecretion
in experimental models has provided compelling evidence
for a key pathogenic role in the induction of airways ob-
struction (13–15). Furthermore, production or expression
of IL-13 and its receptor subunits have been directly linked
to asthma and cells that play key roles in pathogenesis (16–
18). Although these two models have been viewed as inde-
pendent effector pathways, IL-13 has been shown to pro-
mote eosinophilia by IL-5– and eotaxin- (a CC chemokine)
regulated mechanisms, which suggests that these molecules
may cooperate to regulate certain aspects of the asthma
phenotype (19–21).
Although extensive investigations have implicated IL-5–
regulated eosinophilia as a central effector mechanism in
asthma and an important clinical target for the resolution of
this disease, the role of this pathway in the development
and exacerbation of pathogenesis remains highly contro-
versial. In experimental models, the inhibition of the ac-
tions of IL-5 consistently suppress pulmonary eosinophilia
in response to antigen inhalation, however, this effect does
not always correlate with a reduction of AHR (9, 10, 22–
25). Indeed, this dichotomy is highlighted by findings from
our laboratory in which allergic IL-5–deficient (IL-5
 
 
 
/
 
 
 
)
mice of the C57BL/6 strain (10) do not develop antigen-
induced AHR, whereas BALB/c mice develop enhanced
reactivity independently of this factor (23). Recent clinical
trials with humanized monoclonal antibodies raised against
IL-5 limited eosinophil migration into the lung, but also
failed to resolve AHR (26). In a small number of studies,
eosinophils have also been dissociated from the induction
of AHR in asthma (27, 28).
These anti–IL-5 studies indicate that mechanisms may
operate in the allergic lung independently of this cytokine
and eosinophils to induce disease, however, they do not
unequivocally dissociate this cell from pathological pro-
cesses. Although we and others have observed that eosino-
phil trafficking to the allergic lung is profoundly attenuated
in IL-5
 
 
 
/
 
  
 
mice or those treated with anti–IL-5 antibodies
by comparison to wild-type (WT) responses, a significant
residual tissue eosinophilia can persist in these mice after al-
lergen inhalation (9, 10, 22, 23, 25). Often, eosinophils in
IL-5–depleted mice are present in the tissue even though
they are almost absent from bronchalveolar lavage fluid.
Furthermore, the degree of residual tissue eosinophilia di-
rectly correlates with the development of AHR and is un-
der genetic regulation. In allergic IL-5
 
 
 
/
 
  
 
mice, tissue eosin-
ophilia is 10–100-fold greater in the BALB/c strain where
AHR persists in comparison to the C57BL/6 strain where
airways reactivity is abolished (10, 23). Thus, it is important
to recognize that anti–IL-5 treatment may not completely
inhibit the accumulation of eosinophils in the allergic lung
and that the residual cells may still contribute to pathogen-
esis through other regulatory processes.
One possibility is that local chemokine systems can oper-
ate independently of IL-5 to recruit eosinophils into the al-
lergic lung. Of particular interest in allergic inflammation is
the role of the eosinophil chemokine, eotaxin, because of
its demonstrated potency and selectivity for eosinophil re-
cruitment in experimental models and its strong clinical as-
sociation with disease in humans (18, 29–33). Eotaxin pro-
duction is also regulated by IL-13. Furthermore, although
IL-5 is a cofactor for eotaxin-induced eosinophilia, we
have also observed that this chemokine can regulate eo-
sinophil migration independently of IL-5 (29). Similarly,
we have shown that eotaxin plays a more pronounced role
in contrast to IL-5 in regulating eosinophil recruitment to
sites of allergic inflammation of the gastrointestinal tract
(34). Thus, the secretion of IL-13 from activated Th2 cells
may promote eotaxin production and eosinophil accumu-
lation, and this pathway may contribute to disease processes
independently of IL-5.
To investigate the possibility that pathways operated by
eotaxin in the allergic lung can contribute to eosinophil ac-
cumulation and disease progression in the absence of IL-5,
we generated BALB/c mice deficient in both IL-5 and eo-
taxin (IL-5/eotaxin
 
 
 
/
 
 
 
). Our data show that eotaxin plays a
critical role in regulating eosinophil accumulation in the al-
lergic lung independently of IL-5. Eotaxin and IL-5 defi-
ciency not only abolished tissue accumulation of eosino-
phils, but also impaired the ability of antigen-specific
CD4
 
  
 
T cells to produce IL-13 and precluded the develop-
ment of AHR. Thus, IL-5 and eotaxin not only regulate
eosinophil migration, they also supply intrinsic signals that
either directly or indirectly modulate Th2 cell production
of IL-13 and subsequently, bronchoconstriction.
 
Materials and Methods
 
Genetically Manipulated Mice.
 
6–12-wk-old BALB/c mice
were used in all experiments and obtained from the Special
Pathogen Free Facility or the Gene Targeting Facility of the John
Curtin School of Medical Research (Australian National Uni-
versity, Canberra, Australia). IL-5
 
 
 
/
 
 
 
, eotaxin
 
 
 
/
 
 
 
, and IL-5/
eotaxin
 
 
 
/
 
  
 
were each backcrossed for 12 generations with the
BALB/c strain. BALB/c IL-5 transgenic (Tg) mice (
 
 
 
49 trans-
gene copies, male, 6–8-wk-old, and backcrossed to the 12th gen- 
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eration [35]) were obtained from the University of Adelaide
(South Australia, Australia). Mice were treated according to the
Australian National University Animal Welfare guidelines and
were housed in an approved containment facility.
 
Induction of Allergic Airways Disease by OVA Sensitization. 
 
6–8-
wk-old mice were sensitized by intraperitoneal injection of 50 
 
 
 
g
OVA/1 mg alhydrogel (Commonwealth Serum Laboratories) in
0.9% sterile saline. Nonsensitized mice received 1 mg alhydrogel
in 0.9% saline. On days 12, 14, 16, and 18, all groups of mice
were aeroallergen challenged with OVA (antigen) as previously
described (10). 24 h after the last challenge, AHR was measured,
the mice were killed by cervical dislocation, and T cell responses
and inflammation and morphological changes to the airways were
characterized.
 
Isolation of Donor Eosinophils.
 
Donor eosinophils for in vivo
transfer and in vitro stimulation were derived from the peritoneal
cavity of naive IL-5 Tg BALB/c mice and isolated using a FAC-
Star™ Plus flow cytometer (Becton Dickinson) based on the for-
ward, side, and light scatter properties of these cells as previously
described (29). The purity of the eosinophils was measured on
cytospin preparations and was 
 
 
 
98%. The contaminating popula-
tion consisted of macrophages and neutrophils and was devoid of
lymphocytes (unpublished data).
 
Generation of Allergen-specific CD4
 
 
 
 T Cells.
 
OVA-specific
CD4
 
  
 
T cells were derived from mice that had been sensitized
with OVA as previously described. In some experiments, mice
received 2 
 
  
 
10
 
6 
 
eosinophils by intraperitoneal injection on the
day of sensitization and again 3 d later. 6 d after sensitization, re-
cipient mice were killed by cervical dislocation, the spleens were
excised, and the splenocytes were disaggregated. Erythrocytes
were lysed and the washed splenocytes were resuspended at 5 
 
 
 
10
 
6 
 
cells/ml in MLC with 10% heat-inactivated FCS, 
 
l
 
-glutamine
(2 mM), and neomycin sulfate (50 mg/liter). Splenocytes were
then cultured for 4 d at 37
 
 
 
C in the presence of 200 
 
 
 
g/ml OVA
to generate OVA-specific T cells. CD4
 
  
 
T cells were then iso-
lated using high gradient magnetic MiniMACS separation col-
umns (Miltenyi Biotec) as previously described (15). 2 
 
  
 
10
 
6 
 
pu-
rified CD4
 
  
 
T cells were then washed and resuspended in PBS
and transferred to naive recipients. Purified CD4
 
  
 
T cell popula-
tions were also analyzed for OVA-specific cytokine production.
The purity of the enriched CD4
 
  
 
cell fraction was uniformly
 
 
 
96% as determined by flow cytometry (unpublished data) and
was devoid of granulocytes.
 
Antigen-specific Cytokine Production from Purified CD4
 
  
 
T Cell
Populations.
 
T cells (5 
 
  
 
10
 
5 
 
cells/well) were incubated with 25
 
 
 
g/ml freshly isolated mitomycin C–treated splenocytes (5 
 
  
 
10
 
5
 
cells/well) or purified eosinophils (2.5 
 
  
 
10
 
5
 
 cells/well) in com-
plete medium in the presence of 200 
 
 
 
g/ml OVA in 96-well
plates (250 
 
 
 
l/well) for 96 h to determine cytokine production.
Cell-free culture supernatants were then collected and stored in
aliquots at 
 
 
 
70
 
 
 
C until analysis.
 
The Role of CD4
 
  
 
T Cell–derived IL-13 in the Induction of
AHR.
 
2 
 
  
 
10
 
6 
 
CD4
 
  
 
T cells (WT or IL-13–deficient) were in-
jected intravenously to naive recipient BALB/c WT or IL-5/
eotaxin
 
 
 
/
 
  
 
mice. Control mice received PBS vehicle intrave-
nously. 24 h after the adoptive transfer, mice were exposed to an
aerosol of 10 mg/ml OVA in 0.9% saline for 30 min and then ev-
ery day for 6 d. AHR to methacholine was measured 24 h after
the last aeroallergen challenge and lung inflammation and mor-
phology were characterized as previously described (10, 15, 36).
In some experiments, recombinant murine IL-13 or PBS was in-
stilled to the trachea of IL-5/eotaxin
 
 
 
/
 
  
 
mice as previously de-
scribed (20) and AHR was measured 48 h later.
 
Characterization of Lung Morphology.
 
Lung tissue representing
the central (bronchi-bronchiole) and peripheral (alveoli) air-
ways were fixed in 10% phosphate-buffered formalin, sec-
tioned, and stained with Carbol’s chromotrope-hematoxylin
for the identification of eosinophils. The number of eosino-
phils in the central bronchi–bronchiole area were identified by
morphological criteria and quantified as previously described
(10, 36).
 
Stimulation of Peribronchial Lymph Nodes (PBLNs).
 
PBLNs
were excised and filtered through nylon mesh (70 
 
 
 
m). The fil-
trate was then centrifuged at 500 
 
g
 
 for 5 min at 4
 
 
 
C and the cell
pellet was resuspended in red blood cell lysis solution and centri-
fuged at 500 
 
g
 
 for 5 min at 4
 
 
 
C. The resulting pellet was cultured
(5 
 
  
 
10
 
5 
 
cells/well) in complete medium in the presence of 200
 
 
 
g/ml OVA in 96-well plates (250 
 
 
 
l/well) for 96 h. Cell-free
culture supernatants were then collected and stored in aliquots at
 
 
 
70
 
 
 
C until cytokine levels were determined.
 
Analysis of Cytokines by ELISA.
 
IL-13 (R&D Systems), IL-4,
and IL-5 (both from BD PharMingen) concentrations were de-
termined in culture supernatants from OVA-stimulated CD4
 
  
 
T
cells and OVA-stimulated PBLN homogenates by ELISA accord-
ing to the manufacturer’s protocol.
 
Measurement of AHR.
 
Responsiveness to 
 
 
 
-methacholine
(methacholine) was assessed in conscious, unrestrained mice by
barometric plethysmography, using apparatus and software sup-
plied by Buxco Electronics. This system yields a dimensionless
parameter known as enhanced pause (Penh) that reflects changes
in wave form of the pressure signal from the plethysmography
chamber combined with a timing comparison of early and late
expiration. Measurement was performed as previously described
(36). Notably, we have confirmed in the BALB/c strain that
changes in Penh in response to methacholine directly correlate
with changes in airway resistance to this spasmogen (20). Thus,
measuring changes in Pehn reflects alterations in resistance and is
indicative of enhanced airways responsiveness.
 
Stimulation of Purified Eosinophils.
 
2 
 
  
 
10
 
6 
 
FACS
 
®
 
-purified
eosinophils were incubated with 10 
 
 
 
g/ml anti–mouse CD28 for
18 h in complete medium in 24-well culture plates in the pres-
ence or absence of recombinant IL-5 (20 ng/ml). For stimulation
with IgA/anti-IgA, highly purified eosinophils were first incu-
bated with secretory IgA at a final concentration of 5 
 
 
 
g/ml. Af-
ter 1 h of incubation at 37
 
 
 
C, cells were transferred into 24-well
plates and stimulated with 10 
 
 
 
g/ml anti-IgA monoclonal anti-
body for 18 h in the presence of recombinant IL-5 (20 ng/ml).
After an 18-h culture, cell viability was determined by trypan
blue exclusion (
 
 
 
90% viable cells) and RNA was extracted from
 
 
 
2 
 
  
 
10
 
6 
 
eosinophils.
 
Reverse Transcription (RT)-PCR Analysis.
 
Total RNA was
isolated from PBLN cells and eosinophils by standard methods
with RNAzol B (Biotech Laboratories). An RT-PCR procedure
was performed as previously described (37) to determine the rela-
tive quantities of mRNA for various cytokines. The primers and
probes for all genes were purchased from GIBCO BRL. Primer
and probe sequences for HPRT have been described elsewhere
(38). Primer and probe sequences for IL-4, IL-5, IL-13, IL-12,
CCR3, IL-18, and eotaxin are as follows: IL-4: sense, GAATG-
TACCAGGAGCCATATC, antisense, CTCAGTACTACGA-
GTAATCCA, probe, AGGGCTTCCAAGGTGCTTCGCA;
IL-5: sense, GACAAGCAATGAGACACGATGAGG, anti-
sense, GAACTCTGCAGGTAATCCAGG, probe, GGGGGT-
ACTGTGGAAATGCTTAT; IL-13: sense, CTCCCTCTGAC-
CCTTAAGGAG, antisense, GAAGGGGCCGTGGCGAAA-
CAG, probe, TCCAATTGCAATGCCATCTAC; IL-12(p40): 
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sense, CGTGCTCATGGCTGGTGCAAAG, antisense, CTTC-
ATCTGCAAGTTCTTGGGC, probe, TCTGTCTGCAGA-
GAAGGTCACA; CCR3: sense, AAG TAC AGG AAG CTA
CAA ATT ATG, antisense, AGC AGA GTT TTA ATG ATT
CCT GAG, probe, GGCCTTGCAGGACTGGCAGC; IL-18:
sense, ACT GTACAACCGCAGTAATACGG, antisense, AGT-
GAACATTACAGATTTATCCC, probe, GAACAAGATCA-
TTTCCTTTGAGG; and eotaxin: sense, TCCACCATGCA-
GAGCTCCACAG, antisense, CCCACATCTCCTTTCAT-
GCCCC, probe, GGAACACAATGGGACGAGTTAGG. After
the appropriate number of PCR cycles, the amplified DNA was
analyzed by gel electrophoresis and Southern blotting, and de-
tected using the enhanced chemiluminescence detection system
as recommended by the manufacturer (Amersham Pharmacia
Biotech). PCR amplification with the HPRT reference gene was
performed to assess variations in cDNA or total RNA loading be-
tween samples.
 
Generation of Th2 Cells from Naive CD4
 
  
 
T Cells.
 
CD4
 
  
 
T
cells from naive mice were isolated from splenocytes with mag-
netic-activated cell sorting and cultured at 5 
 
  
 
10
 
6 
 
cells/ml in
complete medium in the presence of anti-CD3 (50 ng/ml; clone
2C11), recombinant murine IL-4 (20 ng/ml), and anti–IFN- 
(40  g/ml; clone R46A2) for 4 d to generate Th2 cells (15). In
some experiments, recombinant IL-18 (20 or 200 ng/ml; R&D
Systems) was also added to the cultures. Th2 cells (1.25   106
cells/well) were then restimulated in the presence of anti-CD3
(50 ng/ml) and anti-CD28 (1  g/ml) in 96-well plates (250  l/
well) for 72 h to determine cytokine release. Cell-free culture su-
pernatants were collected and stored in aliquots at  70 C until
analysis by ELISA.
Collection of Sputum Samples. Children with moderate, persis-
tent asthma were recruited from the outpatient department at the
University Children’s Hospital of Freiburg (Freiburg, Germany).
The diagnosis of asthma was based according to the criteria of the
American Thoracic Society (39). The patients were in a stable
condition and had been free of respiratory infections. All patients
were under continuous inhalation treatment with 400–800  g
budesonide per day. Sputum induction was performed as previ-
ously described (40). In brief, 10 min after the inhalation of 200
 g salbutamol, subjects inhaled hypertonic saline (3, 4, and 5%)
via an ultrasonic nebulizer (Ultraneb 2000; De Villbiss) with the
output set at maximum (4.5 ml/min) for three consecutive peri-
ods of 10 min for each concentration. Lung function was re-
corded before the procedure and every 5 min for safety by using
a Masterscope 4.0 (Jaeger). To collect sputum, subjects were
asked to rinse their mouth, blow their nose, swallow water, and
then expectorate the sputum onto a plastic Petri dish after the
first 10-min period of inhalation and every 5 min thereafter. Ad-
equate plugs of sputum were selected to reduce contamination
with saliva and were processed immediately. Sputum processing
was performed as previously described (40). In brief, the weight
of selected plugs was determined and twice their volume of
dithiothreitol 0.1% (sputalysin; Calbiochem) was added. Samples
were placed in a water bath at 37 C for 15 min to ensure the
complete dissolution and PBS was added to achieve a 25-fold di-
luted final concentration. Cell-free supernatant was stored at
 70 C until additional analysis was performed. Eosinophil cat-
ionic protein (ECP; detection limit: 4 ng/ml, diluted sample: 100
ng/ml; Pharmacia & Upjohn) and IL-18 (detection limit: 12 pg/
ml, diluted sample: 300 pg/ml; Medical & Biological Laborato-
ries Co Ltd.) were measured in the supernatants of the selected
plugs. The study was approved by the ethics committee of the
Albert-Ludwigs University of Freiburg (Freiburg, Germany) and
written informed consent from parents and patients was obtained
in advance.
Statistical Analysis. The significance of the differences be-
tween experimental groups was analyzed using Student’s unpaired
t test. Values were reported as the mean   SEM. Differences in
mean values were considered significant if P   0.05. The relation
between variables was calculated using Spearmann’s rank correla-
tion coefficients.
Results
Cooperative Signaling Events between IL-5 and Eotaxin Reg-
ulate AHR and Tissue Levels of Eosinophils. Baseline levels
of airways reactivity were not significantly different be-
tween nonallergic WT, eotaxin / , IL-5 / , or IL-5/
eotaxin /  BALB/c mice (Fig. 1 a). However, antigen
(OVA) inhalation induced a marked AHR in allergic WT,
eotaxin / , and IL-5 /  mice (Fig. 1 a). In contrast, in the
absence of both IL-5 and eotaxin, AHR was completely
abrogated (Fig. 1 a), suggesting that these molecules act in
concert (potentially through eosinophils) to regulate en-
hanced reactivity (data is only shown for 25 mg methacho-
line, but is representative of the full concentration effect
curve to methacholine). To determine the impact of IL-5
and eotaxin deficiency on eosinophil expansion and mi-
gration in response to antigen inhalation in the lung, num-
bers of this leukocyte were quantified in the bone marrow,
blood, and pulmonary compartments of allergic mice defi-
cient in these factors. Eosinophils expanded in the bone
marrow (unpublished data) and blood (Fig. 1 b) compart-
ments of allergic WT and eotaxin /  mice. However, in
the absence of IL-5, eosinophilia in these compartments
was not observed. Although blood and bone marrow eo-
sinophilia was critically regulated by IL-5, the accumula-
tion of eosinophils in the pulmonary compartment was
modulated by both IL-5 and eotaxin (Fig. 1 c). Eosinophil
numbers observed in the airway wall of allergic IL-5 /  or
eotaxin /  mice were markedly decreased in comparison
to those observed in WT mice, whereas in the absence of
both IL-5 and eotaxin, eosinophil accumulation was totally
abrogated (Fig. 1 c). Only occasionally were eosinophils
identified in the perivascular region of the allergic IL-5/
eotaxin /  lung at numbers similar to those seen in nonal-
lergic mice (unpublished data). Notably, although slightly
attenuated, mucus hypersecretion was still a marked fea-
ture in the allergic lung of IL-5/eotaxin /  mice (unpub-
lished data).
These data indicate that both IL-5 and eotaxin can inde-
pendently recruit eosinophils into the lung, but collectively
they provide the primary signals for the homing of this cell
to allergic airways. Importantly, in the absence of IL-5 and
a pronounced blood eosinophilia, mechanisms still exist to
recruit eosinophils into the allergic lung from the basal
eosinophil population. These data also suggest that it is the
residual eosinophil population, which is very pronounced
by comparison with the airways of nonallergic mice, in the
lung of allergic IL-5 /  and eotaxin /  mice that may pro-
mote AHR.1437 Mattes et al.
IL-13 Production by Antigen-specific CD4  T Cells and in
PBLNs Is Impaired in the Absence of IL-5 and Eotaxin. As
signals elicited by CD4  T cells have been shown to play
an obligatory role in the induction of AHR (2), the impact
of IL-5/eotaxin deficiency on CD4  T cell production of
IL-13, IL-4, and IL-5 was examined after their isola-
tion from allergic WT, IL-5 / , eotaxin / , and IL-5/
eotaxin /   mice. After in vitro antigen stimulation of
whole splenocyte populations taken from allergic mice,
CD4  T cells were isolated and restimulated at equivalent
numbers (5   105 cells/well   2   106 cells/ml) with anti-
gen-loaded mitomycin C–treated splenocytes (Fig. 2, a–c).
Stimulation of IL-5 / , eotaxin / , IL-5/eotaxin / , and
WT CD4  T cells under identical conditions promoted the
production of equivalent levels of IL-4 but not IL-13 (Fig.
2, a and b). The level of IL-13 produced by IL-5 / ,
eotaxin / , or IL-5/eotaxin /  CD4  T cells was signifi-
cantly reduced when compared with those derived from
WT mice (Fig. 2 a). Notably, the levels of IL-13 in IL-5/
eotaxin /  CD4  T cell cultures were 10-fold less com-
pared with WT cultures and were further reduced in com-
parison to the levels observed with IL-5 /  or eotaxin / 
mice. The reduced levels of IL-13 did not correlate with an
overall suppression in Th2-type cytokine production, as
IL-5 levels produced by eotaxin /  CD4  T cells and IL-4
levels in all cultures were similar to those observed in WT
CD4  T cell cultures (Fig. 2, b and c).
The limited ability of CD4  T cells isolated from allergic
IL-5/eotaxin /  mice to produce IL-13 also correlated
with the reduced levels of IL-13 and the number of eosino-
phils found in the PBLN. This correlation was also ob-
served in IL-5 /  mice and eotaxin /  mice (unpublished
data). Antigen provocation of WT mice induced a signifi-
cant increase in the number of eosinophils in the PBLN
(50-fold; 7.2   0.5 eosinophils/high power field [HPF]) as
compared with nonallergic mice (0.14   0.06 eosinophils/
HPF). Accumulation of eosinophils in PBLN directly cor-
related with increased levels of IL-13 production within the
lymph nodes (48.5   6.1 ng/ml in allergic WT and not de-
tectable in nonallergic WT in PBLN homogenates). In
contrast, in allergic IL-5/eotaxin /  mice, eosinophil num-
bers (0.73   0.18 eosinophils/HPF) in the PBLN after an-
tigen inhalation were similar to those observed in WT non-
allergic mice and IL-13 levels were markedly diminished
( 7.0   0.4 ng/ml in PBLN homogenates). Thus, eosino-
phil deficiency in IL-5/eotaxin /  mice (and in IL-5 / 
and eotaxin  /  mice, unpublished data) directly correlated
with impaired CD4  T cell production of IL-13 and with
the levels of cytokine generated in the allergic lung. Fur-
thermore, the complete removal of this granulocyte from
pulmonary tissues in IL-5/eotaxin /  mice, which is where
IL-13 levels were the lowest, correlated with the abolition
of airways reactivity to cholinergic stimuli (Fig. 1, a and c).
Collectively, these data show that the abolition of IL-5 or
eotaxin signaling predisposes (potentially due to eosinophil
deficiency) to an intrinsic defect in T cell production of IL-
13 that precludes the development of AHR.
Transfer of IL-13–producing Antigen-specific CD4  T Cells
to Naive IL-5/Eotaxin /  Mice Reconstitutes Normal IL-13
Levels in the Allergic Lung and Induces AHR and Eosinophil-
ia. The observations in allergic IL-5/eotaxin /   mice
suggested that the absence of these molecules resulted in
the abolition of AHR by limiting the ability of CD4  T
cells to produce IL-13. Therefore, we adoptively trans-
ferred WT antigen-specific CD4  T cells that are compe-
tent in their ability to produce IL-4, IL-5, and IL-13 to na-
Figure 1. IL-5 and eotaxin
deficiency abrogates AHR.
Groups of mice (WT, IL-5  / ,
eotaxin / , or IL-5/eotaxin / )
were sensitized with saline (non-
allergic) or OVA (allergic) and
aeroallergen challenged with
OVA. (a) AHR data represent
the percentage increase in Penh
at 25 mg/ml methacholine over
baseline reactivity in the absence
of cholinergic stimuli. The max-
imal response to methacholine
(25 mg/ml) is shown, but these
results are representative of the
full dose response curve. Data is
the mean of six to eight mice  
SEM per group. (b) The per-
centages of blood eosinophils.
Data is the mean   SEM of four
mice per group. (c) Mean num-
ber of eosinophils residing in the
airway wall per 10 similar HPFs
( 1,000) for each group. Data is
the mean   SEM of four mice
per group). *, significant differ-
ences (P     0.05) between re-
spective nonallergic and allergic
groups. Levels of significant dif-
ferences are also indicated for
other groups.
Figure 2. Intrinsic defect in
IL-13 production by antigen-
specific CD4  T cells in the ab-
sence of IL-5 and eotaxin. Pro-
duction of (a) IL-13, (b) IL-4,
and (c) IL-5 by purified OVA-
specific CD4  T cells generated
from WT, IL-5  / , eotaxin / ,
or IL-5/eotaxin /   mice. Cul-
tures were performed in tripli-
cate. CD4  T cells were derived
from splenocytes because these T
cell cytokine profiles were di-
rectly reflective of those ob-
served after the stimulation of
PBLN cultures. Data represent
the mean   SEM of n   4 cul-
tures per group. Significant dif-
ferences (P   0.05) between re-
spective groups are shown.1438 IL-5 and Eotaxin Regulate IL-13 Production by TH2 Cells
ive WT and IL-5/eotaxin /  mice to directly determine
the contribution of T cell–derived IL-13 (in association
with IL-5) to the induction of disease. Transfer of these
CD4  T cells (2   106) into naive WT mice followed by
the subsequent delivery of antigen (OVA) to the airways
induced the hallmark features of allergic airways inflamma-
tion, which included AHR, mucus hypersecretion (unpub-
lished data), and peripheral blood and pulmonary eosino-
philia (Fig. 3, a–c). Adoptive transfer of this CD4  T cell
population into naive IL-5/eotaxin /  mice also induced
AHR to levels observed in WT mice (Fig. 3 a). However,
in the absence of endogenous IL-5 and eotaxin, although
peripheral blood and pulmonary eosinophilia were in-
duced, responses were attenuated in comparison to the WT
(Fig. 3, b and c). Concomitant with the transfer of CD4  T
cells, the levels of IL-4, IL-5, and IL-13 increased in the
lung (PBLN; Fig. 3, d–f). Stimulation of PBLN cultures
from IL-5/eotaxin / – and WT-recipient mice with anti-
gen promoted the production of IL-4, IL-13, and IL-5
(Fig. 3, d–f). The levels of IL-13 and IL-4 produced in
PBLN cultures from IL-5/eotaxin /  mice were similar to
those observed in WT mice (Fig. 3, d and e). In contrast,
the level of IL-5 produced from IL-5/eotaxin /  cultures
was significantly lower than that observed in WT mice
(Fig. 3 f). This latter finding can be explained by the inabil-
ity of the recipient’s endogenous PBLN cells to produce
IL-5 and is consistent with the observed reduction in
peripheral blood and pulmonary eosinophilia in IL-5/
eotaxin /  mice receiving CD4  T cells in comparison
with WT responses (Fig. 3, b and c). Thus, by overcoming
the functional defect in the production of IL-13 and IL-5
within the CD4  T cell compartment, the hallmarks of al-
lergic asthma could be induced in IL-5/eotaxin /  mice.
These data also show that T cell activation processes by an-
tigen are functional in IL-5/eotaxin /  mice.
To further confirm the critical requirement of IL-13 for
the induction of AHR, antigen-specific IL-13–deficient
CD4  T cells, which are only defective in their ability to
produce IL-13, were adoptively transferred to naive IL-5/
eotaxin /  mice (Fig. 4 a). Recombinant mIL-13 was also
instilled into the trachea of mice deficient in both IL-5 and
eotaxin (Fig. 4 b). In contrast to WT CD4  T cells, IL-13–
deficient T cells failed to induce AHR. However, when
only IL-13 was delivered to the pulmonary microenviron-
ment, AHR was induced. These data confirm the essential
requirement of IL-13 in the induction of AHR.
Adoptive Transfer of Eosinophils to IL-5/Eotaxin /  Mice
Reestablishes IL-13 Production from CD4  T Cells. Collec-
tively, the above findings in allergic mice deficient in IL-5
and/or eotaxin lead us to speculate that limitations in the
ability of their CD4  T cells to produce IL-13 may be a di-
rect result of eosinophil deficiency, rather than the absence
of the cytokines themselves. To examine the role of eo-
sinophils in regulating IL-13 secretion from CD4  T cells in
vivo, we purified and adoptively transferred eosinophils
(4   106) into IL-5/eotaxin /  mice and then sensitized these
mice with antigen (OVA). The transferred eosinophil pop-
ulation was highly enriched and did not contain T lympho-
cytes as determined by FACS® analysis and morphological
criteria after cytocentrifugation (unpublished data). 6 d after
sensitization and intraperitoneal injection of eosinophils,
whole splenocyte populations were removed and cultured
with antigen for 4 d. After primary stimulation, CD4  T
cells (2   106 cells/ml) were purified and restimulated with
Figure 3. Adoptive transfer of IL-13–producing CD4  T cells to naive
IL-5/eotaxin /  mice reconstitutes normal IL-13 levels in the allergic
lung and induces AHR and eosinophilia. CD4  T cells (2   106 per
mouse) were adoptively transferred into IL-5/eotaxin /  or WT mice.
Control groups received PBS. (a) AHR. Data represent the percentage
increase in Penh at 25 mg/ml methacholine over baseline reactivity in the
absence of cholinergic stimuli. The maximal response to methacholine
(25 mg/ml) is shown, but these results are representative of the full dose
response curve. Data is the mean of six to eight mice   SEM per group.
(b) The percentage of blood eosinophils. Data represent the mean   SEM
of three or four mice per group. (c) Mean number of airway wall/smooth
muscle eosinophils per 10 similar HPF ( 1,000) for each group. Data
mean   SEM of two or three mice per group. (d–f) Production of (d)
IL-13, (e) IL-4, and (f) IL-5 from PBLN cells after OVA restimulation. T
cell cytokine levels were determined in PBLN culture because these di-
rectly reflect the trafficking of the transferred cells to the lung and the
subsequent release of cytokines in the pulmonary compartment. *, signifi-
cant differences (P   0.05) between control and T cell transferred groups.
Levels of significant differences are also indicated for other groups.
Figure 4. IL-13 plays a critical
role in the generation of AHR.
(a) Adoptive transfer of IL-13–
deficient CD4  T cells (2   106
per mouse) to naive IL-5/
eotaxin /  mice failed to induce
AHR. Control groups received
PBS. (b) In contrast, instillation
of mIL-13 in the lungs of naive
IL-5/eotaxin /   mice induced
AHR. Data is the mean of four
to eight mice   SEM per group.
*, significant differences (P   
0.05) between groups is shown.1439 Mattes et al.
antigen-loaded mitomycin C–treated splenocytes or eo-
sinophils (Fig. 5, a and b). Similarly, CD4  T cells were also
prepared from sensitized WT and IL-5/eotaxin /  mice
that did not receive exogenous eosinophils. Secondary
stimulation of WT CD4  T cells with antigen-loaded sple-
nocytes induced a significant increase in the levels of IL-13
compared with IL-5/eotaxin /  CD4  T cells (Fig. 5 a).
However, when eosinophils were transferred to IL-5/
eotaxin /  mice before sensitization, the levels of IL-13
produced by CD4  T cells after secondary stimulation with
antigen-loaded splenocytes was equivalent to that observed
in WT cultures (Fig. 5 a). To ascertain whether the eosino-
phil was promoting IL-13 production from T cells indi-
rectly or had the ability to directly engage these cells
through antigen presentation, CD4  T cells from all groups
of sensitized mice were subjected to secondary stimulation
in the presence of antigen-loaded eosinophils (Fig. 5 b).
Secondary stimulation of CD4  T cells from WT mice in
the presence of eosinophils produced significantly higher
levels of IL-13 compared with IL-5/eotaxin /  CD4  T
cells (Fig. 5 b), and these levels were similar to those ob-
served in cells stimulated with splenocytes (Fig. 5 a). More-
over, secondary stimulation of CD4  T cells from IL-5/
eotaxin /  mice, which received eosinophils before sensiti-
zation, produced similar levels of IL-13 to those observed
in T cell cultures from WT mice (Fig. 5 b). These data sup-
port the concept that eosinophil deficiency induced in the
absence of IL-5 and eotaxin predisposes to an intrinsic de-
fect in T cells that subsequently impairs the ability of anti-
gen-specific CD4  T cells to produce IL-13.
IL-18 Expression Is Decreased in PBLN of Allergic IL-5/
Eotaxin /  Mice and Up-regulated in IL-5–primed Eosino-
phils. As IL-18 has been identified as an important modu-
lator of Th2 cell immunity and, in particular, a key regula-
tor of IL-13 production from this cell (41), we investigated
the levels of expression of IL-18 in allergic PBLN isolated
from WT, IL-5 / , and IL-5/eotaxin /  mice. RT-PCR
for IL-5, eotaxin, IL-13, and IL-18 was performed and
specificity of PCR products was confirmed by Southern
blot analysis using 30-mer oligonucleotide probes for
HPRT, IL-5, eotaxin, IL-13, and IL-18 (Fig. 6 a). In aller-
gic WT mice all factors were abundantly expressed. In con-
trast, the levels of expression of these factors, in particular
IL-13 and IL-18, were attenuated in the absence of IL-5.
Moreover, in allergic IL-5/eotaxin /  mice, the levels of
IL-13 and IL-18 expression were low or barely detectable
(Fig. 6 a), which also correlates with the low levels of eo-
sinophils in PBLN that were previously described. Thus,
eosinophil deficiency correlated with the decreased expres-
sion of IL-13 and IL-18 in allergic lymph nodes. To deter-
mine if eosinophils could express IL-18, we cultured puri-
fied eosinophils with IL-5 and stimulated these cells with
anti-CD28 or IgA–anti-IgA complex to activate cytokine
gene expression (42). CCR3, the receptor for eotaxin, and
IL-4 were expressed in unstimulated eosinophils (Fig. 6 b).
Stimulation of eosinophils with IL-5 up-regulated the ex-
pression of IL-18. Notably, IL-18 expression was addition-
ally enhanced by the stimulation of IL-5–primed eosino-
phils with anti-CD28 or IgA–anti-IgA complex. Although
IL-12 expression was also induced under these conditions,
we could not detect transcripts for IL-13. These data indi-
cate that eosinophils potentially have the ability to synthe-
size IL-18, which could subsequently influence T cell func-
tion when released into the same microenvironment.
IL-18 Restores IL-13 Production in Polarized Th2 Cells from
IL-5/Eotaxin /  Mice. To define at what stage IL-5 and
eotaxin deficiency may impair IL-13 production from T
cells, and to identify the potential of IL-18 to overcome the
intrinsic defect, we isolated naive CD4  T cells from the
Figure 5. Adoptive transfer of
eosinophils to IL-5/eotaxin / 
mice reestablishes normal pro-
duction of IL-13 from antigen-
specific CD4  T cells. IL-13 pro-
duction from purified CD4  T
cells derived from allergic WT
and IL-5/eotaxin /   mice or
allergic IL-5/eotaxin /   mice
that had been injected with eo-
sinophils intraperitoneally before
sensitization. CD4  T cells stim-
ulated in the presence of OVA
with (a) freshly isolated and mito-
mycin C–treated splenocytes or
(b) with purified eosinophils.
Cultures were performed in trip-
licate. Data represent the mean  
SEM of n   4 cultures per group.
Significant differences (P   0.05)
between respective groups are
shown. Cytokine production was
analyzed from T cells derived
from splenocytes after eosinophil transfer experiments. Eosinophils in-
jected intraperitoneally migrate to the spleen and colocalize with T cells in
this compartment. Thus, by taking T cells from the spleen we know that
they have been exposed to the transferred eosinophil population.
Figure 6. IL-18 expression is decreased in PBLN of allergic IL-5/
eotaxin /  mice and up-regulated in IL-5–primed eosinophils. (a) PBLN
cells from WT, IL-5 / , and IL-5/eotaxin /  were isolated and RT-
PCR was performed for HPRT, IL-5, eotaxin, IL-13, and IL-18. To
confirm specificity, PCR products were probed by Southern blot analysis
using 30-mer oligonucleotide probes for these factors. The mean fold de-
creases in cytokine levels in comparison to WT are as follows: eotaxin in
IL-5 /  (10-fold reduction); IL-13 in IL-5 /  (15-fold reduction) and in
IL-5/eotaxin /  (40-fold reduction); and IL-18 in IL-5 /  (15-fold re-
duction) and IL-5/eotaxin /  (30-fold reduction). PBLN were analyzed
to directly reflect the production of factors within the allergic lung. (b)
Highly purified eosinophils were stimulated with IL-5/anti-CD28 or
IgA–anti-IgA complex for 18 h to activate cytokine gene expression.
RT-PCR was performed for HPRT, CCR3, IL-18, IL-13, IL-4, and
IL-12 (p40). PCR products were probed by Southern blot analysis using
30-mer oligonucleotide probes for these factors.1440 IL-5 and Eotaxin Regulate IL-13 Production by TH2 Cells
spleens of WT, IL-5/eotaxin / , and IL-5 Tg mice. Eo-
sinophils, which localize with T cells in the spleens of WT
mice, are absent in spleens from IL-5/eotaxin /  mice and
overly abundant in this compartment in IL-5 Tg mice (un-
published data). Naive CD4  T cells were then polarized to
the Th2 phenotype under standard conditions in the ab-
sence of antigen and antigen-presenting cells and restimu-
lated with anti-CD28/anti-CD3. Like antigen-specific
CD4  T cells isolated from allergic mice, polarized Th2
cells from IL-5/eotaxin /  mice were limited in their abil-
ity to produce IL-13 (Fig. 7 a) but not IL-4 (Fig. 7 b) when
compared with WT Th2 cells. In contrast, Th2 cells de-
rived from naive IL-5 Tg mice produced exaggerated levels
of IL-13 in response to stimulation (Fig. 7 a, right). Incuba-
tion of naive CD4  T cells isolated from IL-5/eotaxin / 
mice with IL-18 during polarization and subsequent sec-
ondary stimulation restored the ability of these T cells to
produce IL-13 (Fig. 7 c). Stimulation of Th2 cells from IL-
5/eotaxin /  mice with IL-18 (20 ng) produced similar
levels of IL-13 compared to WT cells stimulated with anti-
CD28 and anti-CD3 (Fig. 7 a). These data suggest that
there is an intrinsic and selective dysfunction in IL-13 pro-
duction during CD4  Th2 cell differentiation in the ab-
sence of IL-5/eotaxin. Moreover, the defect in IL-13 pro-
duction is proportionally linked to eosinophil deficiency
and is overcome by signals elicited by IL-18. Although not
conclusive, these data (Figs. 6 and 7) are suggestive that
eosinophils may regulate IL-13 production from CD4  T
cells through IL-18–mediated mechanisms.
IL-18 Correlates with Eosinophilic Airway Inflammation in
Asthma. To determine the potential relevance of our ob-
servations to human disease, we measured the levels of IL-
18 and ECP in the induced sputum of children suffering
from allergic asthma (40). Analysis of IL-18 (mean [min/
max]: 2,385 [300–8,025] pg/ml) and ECP (mean: 1,509
[ 100/4,625] ng/ml) in 23 paired samples showed a highly
significant correlation (rs   0.70, P   0.0002) between this
cytokine and the eosinophil-derived product in the air-
ways. Thus, we could also demonstrate a strong correlation
between IL-18, eosinophils, and allergic inflammation in
the human lung.
Discussion
In this investigation we show that deficiency in IL-5, eo-
taxin, or both molecules predisposes to an intrinsic defect
in T cells that subsequently impairs the ability of antigen-
specific CD4  T cells from allergic mice or in vitro–polar-
ized Th2 cells to produce IL-13. Furthermore, this defect
in T cell production of IL-13 (in IL-5/eotaxin /  mice)
correlates with the abrogation of AHR. Although we can-
not unequivocally exclude the possibility that IL-5/eotaxin
regulate T cell production of IL-13 independently of eosin-
ophils, our data indicate that eosinophil deficiency caused
by the absence of these cytokines predisposes to this intrin-
sic defect in T cells. The number of eosinophils present in
tissues where T cells colocalize at baseline or during allergic
inflammation directly correlates with the subsequent po-
tential of CD4  T cells to produce IL-13. Eosinophils
transferred to IL-5/eotaxin /  mice before sensitization
also restored the ability of antigen-specific CD4  T cells to
produce IL-13. Although the IL-5R   chain, which is es-
sential for IL-5 signal transduction, is expressed in B lym-
phocytes and in limited studies has been implicated in the
generation of cytotoxic T lymphocytes, its expression in
CD4  Th cells has not been observed (43, 44). A direct ef-
fect of IL-5 on this subclass of lymphocyte is therefore un-
likely. Furthermore, CD4  T cell production of IL-5 was
not impaired in allergic eotaxin /  mice (Fig. 2), which
suggests that the T cell defect was not due solely to the ab-
sence of IL-5, but to involved processes downstream of
these molecules. Notably, in allergic IL-5 /  C57BL/6
mice, IL-13 levels (unpublished data) in PBLN were lower
than those reported here in IL-5 /  BALB/c mice, further
linking total tissue eosinophil numbers with IL-13 produc-
tion and the development of AHR.
Our data support recent investigations that show eosino-
phils can modulate CD4  T cell function. Eosinophils in the
allergic lung can present antigen and traffic to local lymph
nodes where they colocalize with T cells (45) and this gran-
ulocyte can induce proliferation and cytokine secretion
from Th2 cells (46). Eosinophils can also secrete a wide
range of T cell growth and chemotactic factors (47). Thus,
evidence is emerging that eosinophils may not only act as
Figure 7. IL-13 production is impaired in polarized Th2 cells derived
from IL-5/eotaxin /  mice, but the defect is overcome by addition of
IL-18 to cultures. Production of (a) IL-13 and (b) IL-4 by CD4  Th2
cells after polyclonal stimulation. Th2 cells were generated from purified
naive CD4  T cells isolated from the spleens of WT, IL-5/eotaxin / , or
IL-5 Tg mice. (c) Release of IL-13 by CD4  Th2 cells after polyclonal
(solid bar) in the absence or presence of IL-18 (20 and 200 ng/ml, respec-
tively). Cultures were performed in triplicate. Data represent the mean  
SEM of n   4 cultures per group. The spleen was used as a source of na-
ive T cells to enable the generation of sufficient Th2 cells.1441 Mattes et al.
terminal effector cells, but can also actively modulate allergic
inflammation by amplifying type 2 cytokine responses.
Notably, eosinophil deficiency did not predispose to a
generalized deficiency in CD4  T cell cytokine produc-
tion, nor in the ability of the immune system to activate
this T cell. IL-4 secretion was not significantly altered in
CD4  T cells derived from mice deficient in IL-5, eotaxin,
or IL-5 and eotaxin. Furthermore, the transfer of WT
CD4  T cells to eotaxin/IL-5 /  mice not only high-
lighted the importance of T cells and presumably T cell–
derived IL-13 for the onset of AHR and pathophysiology,
but also demonstrated that normal activation mechanisms
for T cells can operate in the absence of eosinophils. The
specific role for IL-13 in the mechanism of AHR was dem-
onstrated by the transfer of IL-13–deficient T cells to eo-
taxin/IL-5    mice where AHR did not develop, and the
delivery of IL-13 alone to the airway microenvironment,
inducing AHR, of these factor-deficient mice. Thus, these
data suggest that the CD4  T cell defect may relate specifi-
cally to impaired production of IL-13 and that eosinophils
can provide a factor that either directly or indirectly regu-
lates IL-13 production. The limitation in T cell IL-13 pro-
duction predisposes to the abrogation of AHR.
The molecular mechanisms that regulate IL-13 produc-
tion in T cells are largely unknown. However, we were in-
terested in the role of IL-18 as this cytokine has been iden-
tified not only as a modulator of both Th1 and Th2
development (41, 48), but more importantly as a potent
cofactor for the regulation of the expression of IL-13 from
T cells (41). Notably, in the allergic lymph nodes from
WT, IL-5 / , or IL-5/eotaxin /  mice, the levels of ex-
pression of IL-18 directly correlated with the levels of IL-
13, the production of IL-13 mRNA, and the number of
eosinophils localized to this compartment. Furthermore,
eosinophils primed with IL-5 and stimulated with mole-
cules that promote cytokine production in this cell showed
that IL-18 expression was up-regulated. Thus, eosinophils,
through the secretion of IL-18, may potentially regulate
IL-13 production from CD4  T cells located within the
same microenvironment. Indeed, we were able to show a
direct correlation between the number of eosinophils
within the microenvironment of naive CD4  T cells and
their subsequent ability to produce IL-13 after clonal ex-
pansion to the Th2 phenotype. Th2 cells derived from the
spleens of IL-5/eotaxin /  mice where eosinophils are ab-
sent were limited in their ability to produce IL-13, whereas
Th2 cells generated from the spleens of IL-5 Tg mice
where eosinophils are overly abundant produced exagger-
ated levels of this cytokine in comparison to WT Th2 cells.
Furthermore, the addition of IL-18 to cultures during po-
larization restored the ability of Th2 cells derived from
eosinophil-deficient mice to produce normal levels of IL-
13. Current data on the role of IL-18 in the regulation of
Th2 immune responses are paradoxical (41, 48) as it has
been shown to both suppress and amplify allergic responses.
However, this cytokine has been shown to regulate IL-13
production from Th2 cells and promote eotaxin produc-
tion and eosinophilia (49, 50). Recently, higher serum lev-
els of IL-18 have been observed in patients with acute
asthma exacerbation. Our data in stable asthmatics indicate
a close correlation between IL-18 and ECP in induced
sputum. This result, derived directly from the bronchial
system, further supports a link between IL-18, eosinophils,
and the pathogenesis of allergic airways inflammation.
The synonymous association between IL-5 and eosino-
philia in conjunction with clinical trial data has propagated
the concept that eosinophils are not central mediators of
asthma but rather bystander cells recruited to the airways in
response to aberrant Th2 cell activation. This concept is
also supported by some studies in animal models. However,
these investigations have failed to consider the relevance of
pathways that may recruit eosinophils into tissues indepen-
dently of IL-5 to disease processes. Here we demonstrate
that eosinophils might be recruited to the allergic lung in-
dependently of IL-5 by eotaxin-dependent mechanisms
and that this eosinophilia is directly linked to the develop-
ment of disease. Eosinophilia, albeit reduced, is also a pre-
dominant feature in the lung of IL-5 /  mice infected with
Toxocara canis (51). Thus, although eotaxin and IL-5 coop-
erate to regulate eosinophil recruitment to the allergic lung,
they can also operate independently of one another to in-
duce eosinophil accumulation. However, in the absence of
both of these molecules, eosinophil accumulation in the al-
lergic lung was ablated and AHR did not develop. These
data indicate that although IL-5 can amplify eosinophil re-
cruitment to the allergic lung, the primary role of this cy-
tokine appears to be in the promotion of eosinophilia in
the blood and bone marrow compartments in response to
antigen provocation. Notably, in the absence of IL-5, eo-
taxin induced the recruitment of eosinophils to the lung
without significant blood eosinophilia or expansion of the
eosinophil pool in the bone marrow. Apparently, eosino-
phils produced by steady-state hematopoiesis and/or resid-
ing in tissues can be efficiently recruited by eotaxin to the
allergic lung in the absence of IL-5. In previous investiga-
tions eotaxin has been shown not only to promote eosino-
phil accumulation in tissues, but also induce the release of
this cell and its progenitors from the bone marrow (52).
The lower abundance of eosinophils in the blood of aller-
gic IL-5 /  mice may mask the development of eosino-
philia in this compartment in response to eotaxin. Further,
it is likely that once eosinophils and/or progenitors enter
the circulation in IL-5 /  mice in response to eotaxin they
are rapidly sequestered into the allergic lung. Indeed, evi-
dence is accumulating for a local pulmonary role for eo-
sinophil progenitors in the pathogenesis of allergic disease
(53). Potentially, in the absence of IL-5, eotaxin may regu-
late the recruitment of eosinophils and progenitors to the
allergic lung that then undergo maturation in the Th2 im-
mune environment.
In summary, our data demonstrate that eosinophils are
able to accumulate in allergic lungs of BALB/c mice in the
absence of IL-5 and promote disease. A key role for eo-
sinophils appears to be in the modulation of IL-13 produc-
tion from CD4  T cells. It is tempting to speculate that
within the allergic lung, eosinophils may sequester antigen1442 IL-5 and Eotaxin Regulate IL-13 Production by TH2 Cells
and localize to regional lymph nodes where they modulate
IL-13 production from T cells during expansion by the se-
cretion of IL-18. This mechanism may have evolved to
promote the expulsion of parasites from the intestinal mu-
cosa. Eosinophils loaded with parasitic antigens may en-
hance the production of IL-13 by T cells in gut-associated
lymphoid tissue, which subsequently promotes the expul-
sion of the pathogen by increasing gastrointestinal motility
by amplifying cholinergic responsiveness and enhancing
mucus secretion. Collectively, our findings indicate that
IL-5 and IL-13 signaling systems are not necessarily mutu-
ally exclusive effector mechanisms, and may also be inte-
grated through eosinophils to regulate certain aspects of
allergic disease. The observation that eosinophils may regu-
late disease processes in the absence of IL-5 has important
implications for therapeutic approaches to allergic disor-
ders. It is potentially dangerous to conclude that eosino-
phils do not play a role in generating AHR or other pa-
thologies by using data from treatments that attenuate, but
do not critically reduce eosinophil numbers in the allergic
airways. Finally, our investigations are the first to identify a
fundamental link between the innate (eosinophils) and
adaptive (T cells) immune responses for the regulation of
IL-13 production.
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